Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.78 -4.8%	$12.60	$8.04 ▼ $25.88	$373.73M	2.27	417,520 shs	251,217 shs
CNST Constellation Pharmaceuticals	$33.99	$33.89	$17.00 ▼ $39.30	$1.63B	2.59	940,325 shs	N/A
KNSA Kiniksa Pharmaceuticals International	$28.09 -3.0%	$27.72	$17.82 ▼ $30.69	$2.05B	0.05	555,944 shs	355,269 shs
PLRX Pliant Therapeutics	$1.41 +0.7%	$1.37	$1.10 ▼ $16.10	$86.55M	1.3	1.20 million shs	581,363 shs
ZGNX Zogenix	$26.68	$26.52	$11.03 ▼ $26.90	$1.50B	0.89	3.76 million shs	94 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+1.06%	+9.02%	+42.06%	-36.59%
CNST Constellation Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.84%	+1.30%	+45.47%	+34.02%
PLRX Pliant Therapeutics	0.00%	+13.25%	-4.08%	+5.22%	-87.29%
ZGNX Zogenix	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.74 of 5 stars	3.6	0.0	0.0	0.0	1.2	2.5	0.6
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.3994 of 5 stars	3.5	4.0	0.0	0.0	2.3	3.3	0.6
PLRX Pliant Therapeutics	4.4978 of 5 stars	3.0	5.0	0.0	4.7	3.2	1.7	0.6
ZGNX Zogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	291.87% Upside
CNST Constellation Pharmaceuticals	0.00	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	40.03% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	844.15% Upside
ZGNX Zogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CNST, KNSA, PLRX, ARCT, and ZGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.45	N/A	N/A	$8.90 per share	1.55
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	$8.63 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$481.17M	4.26	N/A	N/A	$6.60 per share	4.26
PLRX Pliant Therapeutics	$1.58M	54.78	N/A	N/A	$5.00 per share	0.28
ZGNX Zogenix	$81.69M	18.36	N/A	N/A	$6.64 per share	4.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
CNST Constellation Pharmaceuticals	-$126.36M	-$2.81	N/A	N/A	N/A	N/A	-33.12%	-29.92%	N/A
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	112.36	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
PLRX Pliant Therapeutics	-$210.30M	-$3.61	N/A	N/A	N/A	N/A	-67.56%	-52.54%	8/6/2025 (Estimated)
ZGNX Zogenix	-$209.38M	-$4.07	N/A	N/A	N/A	-278.38%	-91.20%	-43.60%	N/A

Latest CNST, KNSA, PLRX, ARCT, and ZGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
ZGNX Zogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
CNST Constellation Pharmaceuticals	N/A	15.39	15.39
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
PLRX Pliant Therapeutics	N/A	11.03	11.03
ZGNX Zogenix	0.88	3.63	4.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CNST Constellation Pharmaceuticals	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
PLRX Pliant Therapeutics	97.30%
ZGNX Zogenix	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
CNST Constellation Pharmaceuticals	43.70%
KNSA Kiniksa Pharmaceuticals International	53.48%
PLRX Pliant Therapeutics	8.00%
ZGNX Zogenix	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
CNST Constellation Pharmaceuticals	154	47.92 million	N/A	Not Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable
ZGNX Zogenix	218	56.23 million	53.92 million	Optionable

CNST, KNSA, PLRX, ARCT, and ZGNX Headlines

Recent News About These Companies

After epilepsy setback, Zogenix buys Modis and rare disease drug for $400m

January 2, 2025 | pharmaphorum.comP

Needle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and Zogenix

August 1, 2024 | globenewswire.com

Hwasung Industrial Co Ltd 002460

March 23, 2024 | morningstar.comM

Orally Inhaled Dihydroergotamine

February 13, 2024 | medscape.comM

MRI in Headache

August 25, 2023 | medscape.comM

Kratom: What We Know

August 13, 2023 | medscape.comM

Alcon (NYSE: ALC)

July 6, 2023 | fool.com

Longeveron Inc Ordinary Shares - Class A

May 20, 2023 | morningstar.comM

Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journal

May 10, 2023 | news.google.comN

Global Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examiner

May 8, 2023 | news.google.comN

Global Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examiner

May 8, 2023 | news.google.comN

Needle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPR

May 4, 2023 | news.google.comN

Needle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan News

April 28, 2023 | news.google.comN

The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache

April 25, 2023 | medscape.comM

Long-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan News

April 24, 2023 | news.google.comN

Anti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journal

April 24, 2023 | news.google.comN

Dravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journal

April 19, 2023 | news.google.comN

Form SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.com

April 19, 2023 | news.google.comN

DEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome News

April 18, 2023 | news.google.comN

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journal

April 17, 2023 | news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNST, KNSA, PLRX, ARCT, and ZGNX Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.78 -0.70 (-4.83%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$14.14 +0.37 (+2.65%)

As of 07/11/2025 07:01 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Constellation Pharmaceuticals NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.09 -0.86 (-2.97%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$28.24 +0.15 (+0.52%)

As of 07/11/2025 08:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Pliant Therapeutics NASDAQ:PLRX

$1.41 +0.01 (+0.71%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.36 -0.04 (-3.19%)

As of 07/11/2025 07:26 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zogenix NASDAQ:ZGNX

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time